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Decision making on the route and duration of antibiotic therapy in acute 
cellulitis: A systematic review and meta-analyses considering the effectiveness 
and harms of antibiotic treatment. 
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Compared with guideline recommendations, antibiotic overuse is common in treating 
cellulitis. We conducted a systematic review and meta-analyses on antibiotic route 
and duration of treatment for cellulitis in adults and children. 
Methods 
We searched MEDLINE, EMBASE and trial registries from inception to Dec 11, 2019 
for interventional and observational studies of antibiotic treatment for cellulitis. 
Exclusions included case series/reports, pre-septal/orbital cellulitis and non-English 
language articles. Random-effects meta-analyses were used to produce summary 
relative risk (RR) estimates for our primary outcome of clinical response.  
PROSPERO:CRD42018100602. 
Results 
We included 47/8423 articles, incorporating data from eleven trials (1855 patients) in 
two meta-analyses. The overall risk of bias was moderate. Only two trials compared 
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the same antibiotic agent in each group. We found no evidence of difference in clinical 
response rates for antibiotic route or duration (RR(oral:IV)=1·12, 95%CI 0·98-1·27, 
I2=32% and RR(shorter:longer)=0·99, 95%CI 0·96-1·03, I2 = 0%, respectively). 
Findings were consistent in observational studies. Follow-up data beyond 30 days 
were sparse. 
Conclusions 
The evidence base for antibiotic treatment decisions in cellulitis is flawed by biased 
comparisons, short follow-up and lack of data around harms of antibiotic overuse. 
Future research should focus on developing patient-tailored antibiotic prescribing for 
cellulitis to reduce unnecessary antibiotic use. 
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Cellulitis is the commonest form of acute skin and soft tissue infection (SSTI), 
characterised by spreading redness, oedema and induration, usually affecting the 
lower limb.1 The term encompasses erysipelas, which is no longer considered a 
distinct entity, and does not apply to inflammation associated with collections of pus 
(e.g. around skin abscesses) for which the primary treatment is drainage rather than 
antibiotic therapy.1 Cellulitis is predominantly a community onset infection, typically 
affecting older adults.2 Recent data from the United States (US) show that SSTI 
incidence in older adults almost doubled between 2000 and 2012 (from 67-130 per 
10,000 persons) with the associated healthcare costs tripling to 15 billion USD.3 From 
2000-2018, the proportion of emergency admissions due to cellulitis in England 
increased by more than one third (0·9 to 1·3%).4 Over 90% of patients with cellulitis 
are treated in ambulatory care.5  
The main causative organisms of cellulitis are beta-haemolytic streptococci, especially 
Streptococcus pyogenes, and Staphylococcus aureus6,7  while other bacterial species 
are linked to specific patient risk factors.2  Guidelines recommend antibiotic agents for 
cellulitis based on susceptibility of key pathogens, but clinicians then have three 
decisions as they seek to avoid antibiotic overuse whilst ensuring good treatment 
outcomes for their patients;8 whether intravenous (IV) treatment is indicated; when to 
switch from IV to oral; and what total duration of treatment is needed. Decisions about 
whether to initiate IV or oral treatment should be based on severity of illness9 but 30-
50% of patients eligible for oral therapy receive IV antibiotics and then many remain 
on them for longer than necessary.10-12 International recommendations for treatment 
duration in cellulitis are inconsistent and range from 51,13 to 10-14 days,14,15 but in 
practice durations commonly exceed two weeks.11,12 A recent review addressing 
antibiotic treatment of cellulitis in adults identified four randomised controlled trials 
(RCTs) comparing oral versus IV therapy, none focusing on IV-to-oral switch and five 
trials addressing treatment duration.16 
We aimed to systematically review the literature on decisions about initial treatment 
with IV versus oral therapy, timing of IV-to-oral switch and duration of therapy in 
cellulitis, considering both effectiveness and harms of antibiotic treatment. Where 
randomised trials exist, we conducted meta-analysis, and have also summarised 
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relevant data from non-experimental studies. We considered studies involving both 




Search strategy and selection criteria 
We followed the Preferred Reporting Items for Systematic Reviews and Meta-
Analyses guidelines (checklist in appendix p1).17 We searched MEDLINE, EMBASE, 
the Cochrane Central Register of Controlled Trials, the ISRCTN registry, the U.S 
National Institute of Health ongoing trials register, the Australian and New Zealand 
Clinical Trials Registry and the World Health Organization International Clinical Trials 
Registry from database inception to Dec 11, 2019. Search terms covered the 
population (cellulitis/erysipelas/skin infection) and intervention 
(antibiotics/duration/route) (appendix p4). Only articles in the English language were 
considered. The protocol is available at www.crd.york.ac.uk/PROSPERO, 
CRD42018100602. 
Studies were eligible if they investigated humans (adults or children) treated with oral 
or IV antibiotics for cellulitis. Those including only patients with pre-septal or orbital 
cellulitis were excluded. Studies assessing SSTIs in general were excluded, unless 
data for the cellulitis subpopulation could be separated. Studies that investigated 
antibiotic prophylaxis or solely topical antibiotic therapy were excluded. Both 
interventional and observational studies were included but case series and case 
reports were not. RCTs were restricted to comparisons of shorter versus longer 
antibiotic courses or oral versus IV antibiotics as initial treatment. Observational 
studies were required, as a minimum, to report the average duration of antibiotic 
therapy used and one of the outcome measures below. 
Data extraction and quality assessment 
Titles and abstracts were screened by one author (ELAC) with a random 20% 
screened by another (HJ), calculating inter-observer agreement using Cohen’s 
kappa.18 All potentially eligible full text articles were independently reviewed by two of 
four authors (ELAC, HJ, RG, AS). Any disagreement was resolved by consensus, 
referring to a third author if necessary. Double data extraction was performed 
independently by the same authors on published reports using standardised, pre-
piloted forms (appendix p3). Data were extracted on study methods, population and 
participant characteristics (setting, demographics, comorbidities, illness severity), 
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interventions (antibiotic agent, route, duration and co-interventions), individual patient-
level outcomes (below), key conclusions drawn by authors, and study funding. 
RCTs were assessed for risk of bias using the Cochrane Risk of Bias Tool.19 Non-
randomised studies were assessed using an abridged Strengthening the Reporting of 
Observational Studies in Epidemiology (STROBE) checklist, focusing on items 4-12 
to assess methodological quality.20 Two authors (ELAC, IJO) independently assessed 
the risk of bias and quality of included studies; disagreements were resolved via 
consensus. The quality of the evidence for studies included in the meta-analyses was 
assessed using the Grading of Recommendation, Assessment, Development and 
Evaluation criteria.21  
Outcomes 
Our primary outcome measure was clinical response, defined as improvement or lack 
of progression of signs and symptoms, assessed as a measure of treatment effect at 
a timepoint specified by study authors. Additional secondary outcome measures of 
effectiveness included clinical/therapeutic failure, recurrence, microbiological cure/ 
bacteriological response, mortality, biochemical response and patient-focused 
outcomes. We also considered balancing outcomes e.g. length of stay (LOS), adverse 
events and development of antibiotic resistance. 
Data analysis 
Where there was evidence of substantial clinical heterogeneity, narrative synthesis 
was performed. Where pooling of results was feasible, meta-analysis was performed 
using the random-effects model. One author (IJO) entered the data onto RevMan,22 
which was independently cross-checked by a second author (ELAC). Statistical 
heterogeneity of included studies was assessed using the Chi-square test (threshold 
P<0·1) and the I2 statistic. I2 values <25% were considered to represent low 
heterogeneity, values 25-75% moderate heterogeneity, and values >75% high 
heterogeneity. Results from meta-analyses are presented as RR, with 95% confidence 
intervals (95% CI) and two-sided P values (threshold P<0·05). An assessment of 
publication bias was not performed due to the small number of studies included in 






The initial search yielded 8423 articles. Title and abstract screening identified 604 
articles for full-text screening of which 557 were excluded. Inter-observer agreement 
was moderate at title and abstract screening (Kappa=0·66, 95%CI 0·59-0·73). Among 
the 47 included articles, one described two RCTs yielding a total of 48 studies (figure 
1): 16 RCTs (including one quasi-RCT),23-37 two non-randomised interventional 
studies38,39 and 30 observational studies.40-68 Eleven RCTs were included in two 
separate meta-analyses. 
Figure 2 summarises the risk of bias across the RCTs. In eight RCTs, the method of 
sequence generation or allocation concealment was not adequately reported. Nine 
RCTs were either open-label or failed to report that they were blinded. The overall risk 
of bias across the RCTs was considered moderate. For non-randomised studies; five 
were considered high quality, 19 moderate quality and eight low quality. The risk of 
bias and quality assessment of each individual study are in appendix tables 1-5. 
Only eight studies measured clinical outcomes beyond 30 days. In the remainder, 
outcomes were assessed within 30 days (12/48), within two weeks (12/48), within the 
first 48-72 hours (4/48); 12 studies did not clearly report the timing of outcome 
assessment. 
Evidence for selecting oral versus IV antibiotics 
Five RCTs compared oral versus IV route of initial treatment for adults with cellulitis 
(table 1). All studies were conducted in high-income countries. Four of the five studies 
included patients with cellulitis who were admitted to hospital. All trials included non-
necrotising cellulitis, but various descriptions were used to indicate the severity of 
disease. One study specifically stated included patients must have a severity of 
cellulitis that warranted treatment with IV antibiotics,23 another study stated that 
included patients had to have ‘severe local findings’.27 All studies required patients to 
have a fever of ≥38°C (with one trial also requiring tachycardia of >90 beats/min),23 
but all trials excluded patients with features of severe sepsis. Two studies compared 
antibiotics of the same class in both oral and IV groups. The remainder compared oral 
agents likely to have good efficacy in cellulitis (clindamycin, roxithromycin and 
pristinamycin) with IV penicillin.  
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In terms of treatment effectiveness, three of the five RCTs assessed clinical response 
rates and were included in the meta-analysis (N=397) (figure 3). There was no 
evidence of difference in clinical response rates between oral versus IV groups 
(RR(oral:IV)=1·12, 95%CI 0·98-1·27, I2=32%). The two remaining studies were not 
included in the meta-analysis since they reported different outcome measures. 
Aboltins found no evidence of a difference in mean days until no advancement of the 
area of cellulitis (mean difference -0·49, 95%CI -1·02 to +0·04) and in treatment failure 
rates between oral and IV groups (4% versus 22%, P=0.10).23 Jorup-Rönström 
assessed efficacy by the time to body temperature reduction to ≤37·5°C and found no 
evidence of difference between groups.27 Two RCTs reported similar rates of relapse 
or recurrence of 16% versus 14% at 4 weeks26 and 11% versus 16% at 6 months27 for 
oral versus IV treatment respectively. The single RCT that reported patients’ pain 
scores and satisfaction with treatment found no evidence of differences between 
groups.23  
In terms of treatment-associated harms, all studies reported data on adverse events 
with only one finding evidence of differences between treatment groups; namely a 
higher rate of adverse events in the oral (pristinamycin) versus IV (penicillin) group, 
28% versus 17% (P=0·03).25 However, there was no evidence of difference in the 
proportions of adverse events necessitating discontinuation of study medication 
between the two groups (11% versus 17%, respectively, P=0·17). Two studies 
reported C. difficile-associated diarrhoea as an outcome, but no cases occurred.26,27 
Three studies compared average hospital LOS, which ranged between 3 and 11 days, 
and found no evidence of difference between randomised groups.25-27 No trials 
reported on the development of antibiotic resistance.  
Evidence for timing of intravenous-to-oral switch 
A single RCT compared efficacy of early (24h) versus later (≥72h) switch to oral 
antibiotics in uncomplicated cellulitis requiring IV antibiotics (table 2).28 Resolution of 
cellulitis was achieved in 79% and 84% of patients in the of shorter (24h and longer 
(>72 hour) treatment groups respectively but the study sample size was too small to 
demonstrate non-inferiority. Decreases in patient-reported pain scores were similar 
between groups. The only treatment-associated harm reported was from a patient in 
the shorter group who experienced headaches and non-C. difficile diarrhoea. 
 
 9 
We did not identify any non-randomised comparative studies of different IV to oral 
switch timing. However, six observational studies reported average durations of IV 
antibiotics for both adult and paediatric patients with complicated cellulitis;40-45 these 
were consistently around 1-3 days prior to oral-switch but often ranged up to 14 days 
(table 2, appendix table 6). None of the studies reported relationships between timing 
of IV-to-oral switch and adverse events, frequency of C. difficile infection or antibiotic 
resistance. 
Evidence for overall duration of therapy 
Data on clinical outcomes among patients with cellulitis randomised to either shorter 
versus longer antibiotic durations were available for 1508 patients in 10 RCTs (table 
3). Seven studies recruited only adults, only one outside Europe and North America. 
Most trials reported outcomes for cellulitis as a subset of patients with SSTIs, two of 
these included patients with complicated SSTIs32,33 but most of the other studies 
lacked detail regarding the severity of cellulitis. As part of the inclusion criteria, the 
minimum total lesion surface area was 75cm2 accompanied by at least one regional 
or systemic sign of infection (10-30% of patients had fever at baseline). Four used 
antibiotics of the same class in both groups (macrolides and oxazolidinones) and four 
compared different classes of antibiotics in each group. In each the choice of short-
course agent was based on anticipated longer duration of action. Five used 
azithromycin and three used tedizolid. The difference between shorter and longer 
treatment groups ranged from two to seven days. 
Two trials specifically studied patients with cellulitis and used the same antibiotic agent 
(flucloxacillin) in both shorter and longer duration groups. One included mostly 
outpatients with uncomplicated cellulitis who received oral therapy, the mean age was 
40 years, 16% had diabetes mellitus, 10% had a fever and the average cellulitis 
severity score was 6.5.31 The other trial included hospitalised patients requiring IV 
therapy who were on average 20 years older (mean age 60 years), 24% had diabetes, 
47% had fever and the average severity score was 8.5.35  
In terms of treatment effectiveness, the eight RCTs that studied mainly adults were 
included in the meta-analysis (N=1458, figure 4). Clinical response rates varied from 
49-100% between trials and there was no evidence of difference in response rates 
between shorter versus the longer antibiotic groups (RR(shorter:longer)=0·99, 95%CI 
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0·96-1·03, I2 = 0%). Three RCTs examined bacteriological response to antibiotic 
therapy, defined as the disappearance of a pathogen that was identified from culture 
at baseline after treatment with antibiotic therapy.29,36 One found higher responses in 
the shorter (macrolide) versus the longer (penicillin) group (33% versus 15%, 
P=0·04).29 Another RCT comparing two macrolides found a trend towards a higher 
response rate in the shorter (89%) versus the longer (78%) group.29 In the third RCT, 
100% of patients achieved bacteriological response in both groups.36 
The two trials to describe patient-reported outcomes found no evidence of differences 
in pain and swelling scores between the shorter and longer groups.31,35This was the 
same for the physician reported clinical scores.  
The only RCT to measure clinical outcomes beyond 30 days was the Duration of 
ANtibiotic Therapy for CEllulitis “DANCE” trial which randomised 151 hospitalised 
patients to receive 6 versus 12 days of flucloxacillin and followed patients to day 90.35 
Although there was no evidence of differences between groups at day 28, more 
recurrences occurred in the shorter treatment group compared to the longer group 
between day 28 and day 90 (24% versus 6%, P=0·045). 
Four non-randomised comparative studies reported effectiveness outcomes for 
patients with cellulitis receiving shorter versus longer durations of antibiotic therapy 
(table 4, appendix table 7). Two were non-randomised interventional studies and 
achieved modest reductions in antibiotic duration after implementing new 
management guidelines/ protocols for cellulitis.38,39 Three studies found no evidence 
of a reduction in effectiveness with shorter treatment durations.38,39,46 Conversely, one 
study that focused on children reported a significantly higher odds ratio (OR) of 
treatment failure for patients treated with short-course IV therapy versus inpatient IV 
therapy (OR=7·2, 95%CI 1·6-33·1), and outpatient oral antibiotics (OR=3·2, 95%CI 
1·3-8·3).47 The duration of short-course IV therapy was not clearly defined but 73% of 
patients in this group received ≤2 doses of IV antibiotics. 
We identified a further twenty-two studies which reported the average length of 
antibiotic treatment for patients with cellulitis and at least one relevant outcome 
measure (appendix tables 8 and 9). These studies included populations that were 
generally older, with a higher illness severity and more comorbidities than those 
recruited to the RCTs. For instance, studies of inpatients had a mean age range from 
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48 to 70 years and 20-35% had diabetes. Eleven studies included inpatients and 
reported an average length of antibiotic treatment of 5-17 days.40,46,48,49,52-54,57,58 
Clinical response rates were all above 85%, failure rates ranged from 5-12% and 
recurrence rates from 0-17%. Eleven studies, including those treated as 
outpatients/OPAT, reported an average length of IV therapy of 2-7 days and an 
average overall treatment duration of 6-10 days.59-69 Clinical response rates ranged 
from 85-97%, failure rates from 5-22% and recurrence rates from 0-6%. 
Across these studies, patient factors emerged as the key determinants of clinical 
response, while no evidence of associations between duration of therapy and outcome 
was reported. In studies comparing patients with better versus worse outcomes, 
groups with poorer outcomes had higher proportions of patients with prior cellulitis, 
sepsis at presentation and comorbidities (including diabetes, immunosuppression, 
obesity and venous insufficiency).40,48,50,55,60,62 
With regards to treatment-associated harms, data on adverse events were not 
reported separately for cellulitis patients within SSTI trials, but overall, three trials 
found a higher incidence of gastrointestinal side-effects among patients receiving 
longer treatment (linezolid and erythromycin) versus shorter treatment (tedizolid and 
azithromycin).29,32,33 One trial found no difference in gastrointestinal side effects 
between groups.34 Only two of these reported that no cases of diarrhoea were 
associated with C. difficile.33,34 One RCT found a higher proportion of side-effects in 
the shorter (azithromycin) versus the longer (cloxacillin) group, but severe events 
requiring study withdrawal were more frequent in the longer group.29 No trials reported 
on the development of antibiotic resistance. 
Evidence from paediatric studies 
There were 7 studies that focused on paediatric populations.36,37,44,45,47,58,68 Overall, 
the paediatric studies included a lower proportion of patients with lower limb cellulitis 
(~40%) compared to adult studies. Only three of the studies stated the severity of 
infection, which was reported as uncomplicated moderate/severe cellulitis.44,45,68 None 
of the paediatric studies compared oral to IV antibiotic therapy. 
Two of the paediatric observational studies reported average IV-to-oral switch 
durations between 1.8-2.5 days with a maximum duration of 2.6 days,44,45 compared 
to adult studies where the maximal average duration was 15 days. The average total 
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duration of antibiotic therapy reported in paediatric studies was 8-11 days with 
treatment failure rates of 0-5%, compared to an average duration of 5-17 days in adults 
with failure rates from 5-22%. 
Two RCTs compared shorter versus longer duration of antibiotic therapy in 
children.36,37 The trials were conducted in low- and middle-income countries as 
opposed to adult studies where the majority were conducted in high-income countries. 
They both compared different classes of antibiotics in each group. Similar to the adult 
studies, the choice of short-course agent was based on anticipated longer duration of 
action. However, the short-course therapy duration was shorter at 3 days versus 5-6 
days in adult studies. The clinical response rates of 81-100% were comparable to 




We have undertaken a comprehensive systematic review of all available published 
evidence supporting decisions about the initial route of administration and duration of 
antibiotic therapy for adults and children with cellulitis. Our findings expand on those 
of a recent review which concluded there is a lack of evidence to support use of IV 
over oral antibiotics and treatment for longer than 5 days in cellulitis.16 The findings of 
a recent trial by Cranendonk et al. highlight that more patients can achieve good long-
term outcomes with more prolonged therapy.35 We have also considered data from 
non-randomised studies and paediatric studies but crucially we have considered 
potential harms of antibiotic therapy, highly relevant to clinicians aiming to optimise 
antibiotic treatment in cellulitis. We have identified 48 relevant studies, many of low or 
very low quality, whose interpretation is further hampered by the heterogeneity of 
outcome measures, highlighted previously as a major limitation in this area.70 Further 
general limitations of the evidence are vagueness of the case definition of cellulitis, a 
potential misdiagnosis rate of ~30%,71 and the fact that participants had often received 
antibiotics prior to enrolment, minimising differences in treatment effectiveness 
between groups.72,73 
Currently, the available evidence suggests that for adults with cellulitis clinical 
response rates are similar for initial oral and IV antibiotic treatment. While this is the 
consistent finding of five trials, all are of low or very low quality. None provide data 
relevant to patients with complicated disease or markers of sepsis. Another key 
limitation is that studies often compare agents of different classes. Only two trials 
compare antibiotic route using drugs of the same class and two trials compare oral to 
IV agents with different anti-staphylococcal activity. Therefore, their findings can only 
be applied in clinical practice with great caution and may be affected in settings with 
differing epidemiology of S. pyogenes and S. aureus. Nevertheless, overall, these 
trials indicate that if initial oral therapy is less effective than initial IV the difference is 
likely to be <2%. However, they do not provide evidence that oral treatment is superior 
to IV treatment through any balancing treatment-related harm outcomes such as side-
effects, C. difficile infection or antibiotic resistance.  
The question of timing of IV-to-oral switch has been addressed in only a single trial 
which was too small to demonstrate non-inferiority and again included only a subset 
of patients with uncomplicated cellulitis.28 
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Although we identified ten randomised trials providing evidence on duration of therapy, 
a major limitation of this evidence base is that eight of the trials use short-course 
treatment with agents anticipated to have longer durations of action compared to the 
longer-course agent used. For instance, azithromycin is used as the short-course 
agent in half of the trials on duration but is known to have a longer serum half-life than 
the other antibiotics. The comparisons are therefore severely flawed and their findings 
of limited relevance to clinical decision making. Current guidelines recommending 5 
days treatment of cellulitis1,13 are based on a single trial that used levofloxacin, which 
is not a recommended first-line treatment.31 Overall these trials indicate that for early 
clinical cure, if short-duration treatment of cellulitis is associated with any loss of 
effectiveness, this is likely to be small (<4%). The one study which found shorter 
treatment to be associated with reduced early clinical cure reported 7.2% failure for 
the cohort overall.47 This illustrates an important point. Across all the studies reviewed, 
the overwhelming majority of patients achieved clinical success irrespective of the 
initial route or duration of therapy. Patients with comorbidities, such as diabetes or 
who have experienced previous cellulitis, may be at increased risk of treatment failure 
but the value of IV or prolonged treatment in these patients remains unproven. 
There is a particular lack of data around outcomes beyond 30 days to allow an 
assessment of the impact on recurrence. A particularly striking finding of the DANCE 
trial was increased recurrence up to 90 days among patients receiving shorter initial 
therapy.35 These results suggest that recurrence may be due in part to recrudescence 
of infection rather than reinfection and that long-term recurrence may be tractable to 
optimised initial therapy.35 
The paediatric studies we have identified illustrate important differences compared 
with adult disease. In particular that fewer patients have lower limb disease and that 
treatment durations and recurrence rates are lower. That two paediatric trials were 
conducted in low- and middle-income countries reflects the greater incidence of 
paediatric streptococcal skin infection in hotter climates and overcrowded 
communities. Nevertheless, findings of the paediatric studies that short duration oral 
therapy is highly effective in cellulitis are entirely consistent with those of studies in 
adults.  
Our study has major strengths. We conducted an extensive literature search across 
all major relevant databases including observational studies. This allowed us to 
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include evidence which informs clinical practice but is not captured in existing 
overviews of this literature, and to include patients who would not ordinarily have been 
enrolled into trials because of significant comorbidities and illness severity. By 
addressing both effectiveness and treatment-related harms our analysis highlights a 
major gap in the evidence in this field. Unless antibiotic-reduction strategies are 
superior in ways which are meaningful to individual patients (e.g. fewer adverse 
effects, less antibiotic resistant infections) even marginal concern about loss of 
effectiveness will limit translation of findings into practice.74 
Our study has several limitations. We have only searched for articles in English and 
did not search unpublished/grey literature. It is possible but unlikely that we have 
missed evidence which would have changed our conclusions. We have been unable 
to assess the impact of publication bias due to the small number of studies included 
in each meta-analysis (<10). The small number of studies available may make the 
random-effects meta-analysis approach we have used unreliable, but this remains the 
most appropriate method.75 There is a risk that some relevant studies could have been 
incorrectly excluded as only 20% of identified papers underwent dual title and abstract 
screening. However, there was substantial agreement between reviewers for dual 
screened studies (1465/1550, 95%) and it is unlikely we have missed evidence which 
would have changed our conclusions. We chose to use an abridged STROBE 
statement to assess the quality of observational studies as there is no consensus on 
the optimal tool to use. While STROBE was not designed for this purpose, it provides 
a useful recommendation of the essential information required to assess the conduct 
of observational studies.76 
In summary although the efficacy of oral antibiotics in cellulitis is long established,77,78 
there is a striking lack of evidence that initial IV therapy or treatment beyond 5-7 days 
are more effective than initial oral or short course treatment. However, this does not 
preclude initial IV treatment and prolonged therapy being more effective in some 
scenarios. This is particularly the case for commonly used agents such as beta-
lactams, since most studies have used less widely used agents, and for patients with 
complicated disease, who have been excluded from most studies. Indeed, the DANCE 
trial highlights that although most patients achieve lasting cure with short durations of 
therapy, a small number of patients do require longer treatment.35 The challenge for 
future research is personalising treatment decisions about duration of therapy. The 
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evidence is further limited by inappropriate comparisons, heterogenous outcomes, 
and lack of long-term follow up. In particular, the lack of data around the harms of IV 
and prolonged antibiotic treatment hampers clinical decision making. It is likely this 
contributes to clinicians choosing to exceed guideline recommendations. 
Observational data suggest that prior cellulitis, illness severity and the presence of 
certain comorbidities are likely to be important in influencing clinical outcomes. Future 
research should focus on developing patient-tailored recommendations for antibiotic 
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